Calcitonin Gene-Related Peptide Inhibitors and Cardiovascular Events in Patients With Migraine: A Retrospective, Observational, Cohort Study
Abstract
Background & Objectives: Calcitonin gene-related peptide (CGRP) inhibitors have entered widespread use in the United States (US) for treatment of migraine but data on their cardiovascular risk profile are lacking. The objective of this study was to determine whether exposure to a CGRP inhibitor is associated with cardiovascular events in patients with migraine. Methods: Retrospective, observational, cohort study using computerized claims data from a proprietary, insurance-based registry – Marketscan (by Merative). Beneficiaries with at least one claim related to a migraine diagnosis and continuous coverage for at least 12 months prior to migraine diagnosis were included. Using a sequential trial framework, the rate of cardiovascular events was computed in those who did and did not initiate a CGRP inhibitor, using both crude estimates and those derived in propensity score-overlap weighted cohorts. Adjusted hazard ratios (HR) and corresponding 95% confidence intervals (CI) were computed. The principal exposure was initiation of any CGRP inhibitor. The primary end point was a composite of myocardial infarction, cerebral ischemic stroke, revascularization, peripheral arterial disease, or central retinal artery occlusion. Secondary end points included each component individually. A falsification end point (humeral fracture) was included. Results: In total, 900,370 beneficiaries (median age 41 [Q1, Q3: 31, 51]; 77.8% female) were included of whom 58,679 initiated a CGRP inhibitor…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.